BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

US FDA Approves BeOne’s TEVIMBRA-ZIIHERA Combination for First-Line HER2+ Gastroesophageal Cancer

TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ ...

August 27, 2026 | News

Metabolon Completes Gates Foundation-Funded Metabolomics Studies to Advance Women’s and Infant Health

nnovative sample collection methods developed through Gates Foundation-funded grant enable high-quality metabolomics biomarker discovery in populations fro...

August 27, 2026 | News

China Accepts Laekna’s NDA for Afuresertib in Advanced Breast Cancer

Laekna (2105.HK) announced that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China'...

August 13, 2026 | News

Haleon, A*STAR Launch Centrum Study on Metabolic Health in Midlife Asian Women

A new clinical study on the multivitamin and mineral supplement Centrum is designed to generate evidence on metabolic health in midlife Asian women - a g...

August 12, 2026 | News

Kelun-Biotech's TROP2 ADC sac-TMT Advances Toward First-Line TNBC Approval in China

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application of its trophoblas...

August 03, 2026 | News

EU CHMP Backs Enhertu Plus Pertuzumab as First New First-Line HER2 Positive Metastatic Breast Cancer Treatment in Over a Decade

Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by ...

July 28, 2026 | News

Sofinnova-Backed Myricx Bio to Join Novartis in Up to $1.5 Billion ADC Deal

Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exit The proposed acquisition combines th...

July 07, 2026 | News

Innovent and Lilly Expand China Oncology Partnership with Verzenios Commercialisation Agreement

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

July 01, 2026 | News

AnHorn Medicines Secures FDA IND Clearance for First-in-Class CIPN Prevention Candidate

AnHorn Medicines announced that its lead neuroprotective candidate AH-008, being developed for the prevention of chemotherapy-induced peripheral neuro...

June 24, 2026 | News

Gesynta Pharma Reaches 50% Patient Enrollment in Phase II Endometriosis Trial of Vipoglanstat

Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190...

June 18, 2026 | News

Akeso Enrols First Patient in Phase Ib/II Trial of Next-Generation HER3 ADC AK138D1 for Advanced Breast Cancer

Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally...

June 17, 2026 | News

Kazia Therapeutics Expands Paxalisib TNBC Trial Following Encouraging Early Safety Data

Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data Kazia Therapeutics Limited (NASDAQ...

May 28, 2026 | News

AstraZeneca And Daiichi Sankyo Expand ENHERTU Into Early HER2 Positive Breast Cancer Treatment In The US

Approved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on DESTINY-Breast05 Phase III trial ...

May 19, 2026 | News

Henlius And Organon Secure European Approval For First Pertuzumab Biosimilar POHERDY

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHE...

May 01, 2026 | News

Stay Connected